Literature DB >> 1841728

Thyroid hormone use: trends in the United States from 1960 through 1988.

S C Kaufman1, T P Gross, D L Kennedy.   

Abstract

Thyroid hormone preparations comprised over 1% of all prescriptions filled by retail pharmacies during 1988 in the conterminous United States, i.e., the 48 contiguous states. Their large market share gives the patterns of their use substantial public health importance. This article describes prescription thyroid hormone use in the United States from 1960 through 1988, using pharmaceutical marketing research data collected from panels of retail pharmacies and office-based physicians. Although the use of natural products has declined by over 50% since 1960, about one fourth of all thyroid hormone prescriptions were for natural preparations as recently as 1988. Per capita thyroid mentions (i.e., patient-physician contacts during which a thyroid agent of any kind was recommended, prescribed, dispensed, administered, ordered to be given by a hospital, or given as a sample) doubled during this period among those over 59 years old. Per capita mentions for synthetic thyroid products increased fourfold and tenfold among men and women in this age group, respectively. Use for weight loss, despite the label's boxed warning indicating it to be ineffective and potentially dangerous, has diminished but persists. Obesity was second only to hypothyroidism among the diagnoses underlying thyroid product mentions.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1841728     DOI: 10.1089/thy.1991.1.285

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  14 in total

Review 1.  Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism.

Authors:  Wilmar M Wiersinga
Journal:  Nat Rev Endocrinol       Date:  2014-01-14       Impact factor: 43.330

2.  Thyroid hormone therapy: past, present, and future.

Authors:  David S Cooper; Leonidas H Duntas
Journal:  Endocrine       Date:  2019-10-15       Impact factor: 3.633

Review 3.  Adverse effects of thyroid hormone preparations and antithyroid drugs.

Authors:  L Bartalena; F Bogazzi; E Martino
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 4.  Individualized Therapy for Hypothyroidism: Is T4 Enough for Everyone?

Authors:  Matthew D Ettleson; Antonio C Bianco
Journal:  J Clin Endocrinol Metab       Date:  2020-09-01       Impact factor: 5.958

Review 5.  The isolation of thyroxine (T4), the discovery of 3,5,3'-triiodothyronine (T3), and the identification of the deiodinases that generate T3 from T4: An historical review.

Authors:  John C Morris; Valerie Anne Galton
Journal:  Endocrine       Date:  2019-06-29       Impact factor: 3.633

6.  Optimal Hormone Replacement Therapy in Hypothyroidism - A Model Predictive Control Approach.

Authors:  Tobias M Wolff; Johannes W Dietrich; Matthias A Müller
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-24       Impact factor: 6.055

7.  Optimal Thyroid Hormone Replacement.

Authors:  Jacqueline Jonklaas
Journal:  Endocr Rev       Date:  2022-03-09       Impact factor: 25.261

8.  The History and Future of Treatment of Hypothyroidism.

Authors:  Elizabeth A McAninch; Antonio C Bianco
Journal:  Ann Intern Med       Date:  2016-01-05       Impact factor: 25.391

Review 9.  Liothyronine and Desiccated Thyroid Extract in the Treatment of Hypothyroidism.

Authors:  Thaer Idrees; Scott Palmer; Rui M B Maciel; Antonio C Bianco
Journal:  Thyroid       Date:  2020-05-12       Impact factor: 6.568

10.  Benefits and Harms of Levothyroxine/L-Triiodothyronine Versus Levothyroxine Monotherapy for Adult Patients with Hypothyroidism: Systematic Review and Meta-Analysis.

Authors:  Juan Manuel Millan-Alanis; José Gerardo González-González; Andrea Flores-Rodríguez; Naykky Singh Ospina; Spyridoula Maraka; Pablo J Moreno-Peña; Juan P Brito; Camilo González-Velázquez; René Rodríguez-Gutiérrez
Journal:  Thyroid       Date:  2021-09-28       Impact factor: 6.568

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.